Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects

Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1

(2017) Jia-Horng Kao et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

A Review of Daclatasvir Drug–Drug Interactions

(2016) Tushar Garimella et al.   ADVANCES IN THERAPY

Transporter-Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug-Drug Interactions of Montelukast

(2016) MV Varma et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pre-absorption physicochemical compatibility assessment of 8-drug metabolic cocktail

(2016) Ching Kim Tye et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection

(2016) Joji Toyota et al.   JOURNAL OF GASTROENTEROLOGY

Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis

(2016) Lucy Platt et al.   LANCET INFECTIOUS DISEASES

Global epidemiology and burden of HCV infection and HCV-related disease

(2016) Aaron P. Thrift et al.   Nature Reviews Gastroenterology & Hepatology

Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug–Drug Interactions

(2015) Timothy Eley et al.   CLINICAL PHARMACOKINETICS

Beclabuvir for the treatment of hepatitis C

(2015) Ivan Gentile et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated Cirrhosis

(2015) Andrew J. Muir et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection

(2015) Fred Poordad et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Multiplexed LC-MS/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma

(2015) Hao Jiang et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Preclinical Characterization of BMS-791325, an Allosteric Inhibitor of Hepatitis C Virus NS5B Polymerase

(2014) Julie A. Lemm et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Pharmacokinetics of Daclatasvir and Asunaprevir Administered in Combination in Studies in Healthy Subjects and Patients Infected with Hepatitis C Virus

(2014) Timothy Eley et al.   CLINICAL DRUG INVESTIGATION

Discovery and Preclinical Characterization of the Cyclopropylindolobenzazepine BMS-791325, A Potent Allosteric Inhibitor of the Hepatitis C Virus NS5B Polymerase

(2014) Robert G. Gentles et al.   JOURNAL OF MEDICINAL CHEMISTRY

Burden of HIV and hepatitis C co-infection: the changing epidemiology of hepatitis C in HIV-infected patients in France

(2014) Patrice Cacoub et al.   LIVER INTERNATIONAL

The Basel Cocktail for Simultaneous Phenotyping of Human Cytochrome P450 Isoforms in Plasma, Saliva and Dried Blood Spots

(2013) Massimiliano Donzelli et al.   CLINICAL PHARMACOKINETICS

451 EVALUATION OF PHARMACOKINETIC DRUG–DRUG INTERACTION (DDI) BETWEEN BMS-791325, AN NS5B NON-NUCLEOTIDE POLYMERASE INHIBITOR, DACLATASVIR AND ASUNAPREVIR IN TRIPLE COMBINATION IN HCV GENOTYPE 1-INFECTED PATIENTS

(2013) X. Wang et al.   JOURNAL OF HEPATOLOGY

Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)

(2012) Fiona McPhee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

(2010) Min Gao et al.   NATURE